特定领域的认知障碍受到阿尔茨海默病的差异影响,包括病理负担和传播
Stephanie Doering1, Nicole S McKay1, Nayid Jana1
1Washington University School of Medicine, Saint Louis, MO, United States.
Imaging neuroscience (Cambridge, Mass.)
|June 19, 2025
概括
在阿尔茨海默氏症 (AD) 中,tau负担和tau传播程度都与认知能力下降相关. 的传播范围对早期临床前缺陷更敏感,而负担更好地预测了整个认知领域的未来下降.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学成像技术 生物医学成像技术
背景情况:
- 陶氏病理是阿尔茨海默病 (AD) 的标志性特征,通常在与记忆相关的区域进行评估.
- 异质的陶传播模式与记忆之外的各种认知障碍相关.
- 之前的工作建立了一个衡量量tau传播范围的指标,对非典型模式敏感.
研究的目的:
- 评估tau传播程度和早期AD领域特定认知障碍之间的关系.
- 为了比较tau负担与tau传播程度在预测认知和临床进展方面的实用性.
主要方法:
- 在529名参与者中利用了基线的定子发射断层扫描 (PET) 和神经心理测试.
- 根据粉样蛋白PET状态和临床痴呆评分 (CDR) 将参与者分类为疾病阶段.
- 量化了tau负担 (Tau指数) 和tau传播范围 (Tau空间传播),并与认知复合物 (一般,情节性,语义,工作记忆,注意力/处理速度) 相相关.
主要成果:
- 的负担和传播程度都与症状AD的认知障碍有显著的相关性.
- 陶荷重与情节和语义记忆密切相关;陶传播范围与一般认知 (Knight PACC) 和注意力/处理速度有关,特别是在临床前的AD.
- 陶氏负担解释了纵向认知和临床进展的变异性比陶氏传播范围更大.
结论:
- 负荷和传播范围为早期AD进展提供了互补的见解.
- 在临床前阶段,tau传播范围可能会捕捉到更广泛的认知缺陷,包括注意力/处理速度.
- 陶荷重是跨越认知领域和临床进展的纵向衰退的更好的预测指标.
相关概念视频
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
01:30Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265